Jubilant Organosys‘ Bangalore based subsidiary Jubilant Biosys has formed an alliance with BioLeap, LLC, USA. The duo will combine BioLeap’s leading edge computational fragment based drug design platform with Jubilant’s know-how in chemistry, biology and crystallography for offering a valuable pre-clinical drug development platform.
The said platform would provide customers services from lead identification and optimization to IND (Investigational New Drug) candidate selection, for multiple therapeutic areas.
BioLeap’s platform helps in reducing the time and cost of traditional screening methods as it quickly predicts binding information providing drug designers new insights to efficiently create novel molecules and /or improve existing molecules without the limitations of library screening.